Innovative therapeutic approaches for patients with HER2-positive breast cancer Journal Article
| Authors: | Taurelli Salimbeni, B.; Ferraro, E.; Boscolo Bielo, L.; Curigliano, G. |
| Editors: | Al Jarroudi; O.; El Bairi, K.; Curigliano, G. |
| Article Title: | Innovative therapeutic approaches for patients with HER2-positive breast cancer |
| Abstract: | Overexpression of human epidermal growth factor receptor 2 (HER2), a transmembrane tyrosine kinase receptor, has been described in about 15–20% of breast cancer (BC) and is associated with poor outcomes. Trastuzumab is the first anti-HER2 monoclonal antibody (mAB) that blocks receptor activity but it also activates immune response against cancer cells, thus, revolutionizing the prognosis of patients with HER2-positive BC. Over the years, new therapies have been developed, including other mAbs and tyrosine kinase inhibitors (TKIs) that required multimodal approaches with chemotherapy to optimize their anticancer activity. This chapter gives a comprehensive overview of the last advancements including new approaches and future combinations, which seem to be very promising in overcoming resistance to the traditional anti-HER2 treatments. A modern therapeutic algorithm should include treatment options based on tumour patterns and a patient-centred approach. A proper patient’s selection is crucial to derive maximal benefits from a treatment strategy and emerging biomarkers should be integrated along with the HER2 status, which is currently the only validated biomarker in the context of HER2-positive disease. These biomarkers might include molecular features with reported prognostic/predictive significance, such as phosphatidylinositol 3’ -kinase (PI3K) or mitogen-activated protein kinase (MAPK) pathways, programmed cell death protein ligand 1 (PD-L1), and tumour-infiltrating lymphocytes (TILs), which all affect prognosis and response to treatments. © The Author(s), under exclusive license to Springer Nature Switzerland AG 2023. |
| Keywords: | signal transduction; fatigue; doxorubicin; capecitabine; paclitaxel; cancer patient; tumor associated leukocyte; lymphocytes, tumor-infiltrating; biomarkers; biological marker; cyclophosphamide; breast neoplasms; tumor antigen; docetaxel; monoclonal antibody; protein tyrosine kinase inhibitor; cancer vaccine; breast tumor; taxane derivative; trastuzumab; anthracycline; lapatinib; immunocompetent cell; keratitis; neratinib; pertuzumab; ertumaxomab; conjunctivitis; trastuzumab emtansine; immune checkpoint inhibitor; bispecific antibody; human epidermal growth factor receptor 2 positive breast cancer; her2-positive breast cancer; humans; human; female; trastuzumab deruxtecan; rc 48; tucatinib; zenocutuzumab; zanidatamab; margetuximab; anti-her2 antibodies; alt p7; anvatabart opadotin; bat 8001; blarcamesine; bpx 603; cct303 406; cinrebafusp alfa; ct 0508; disitamab vedotin; gancotamab; glsi 100; gq 1001; kn 026; nelipepimut s; pertuzumab zuvotolimod; pf 06804103; sar 443216; tak 522; trastuzumab botidotin; trastuzumab duocarmazine; trastuzumab vedotin |
| Journal Title: | Cancer Treatment and Research |
| Volume: | 188 |
| ISSN: | 0927-3042 |
| Publisher: | Springer |
| Date Published: | 2023-01-01 |
| Start Page: | 237 |
| End Page: | 281 |
| Language: | English |
| DOI: | 10.1007/978-3-031-33602-7_10 |
| PROVIDER: | scopus |
| PUBMED: | 38175349 |
| DOI/URL: | |
| Notes: | This book chapter is part of the book Cancer Treatment and Research: Innovative Concepts (978-3-031-33601-0) -- Source: Scopus |
